FDA Plays

[kei]

OPXA - up 20% moving up...HOD $2.20...Relapse Rate compared to those on placebo (OPXA) 1.83 : Co presents clinical data highlighting important efficacy data from Opexa's Phase IIb TERMS clinical trial in a subpopulation of patients that had previously not been exposed to or taken any drugs for the treatment of their MS. In this treatment-free or "naive" subpopulation, patients treated with Tovaxin demonstrated a significant improvement in Annualized Relapse Rate compared to those on placebo. In patients who had at least one relapse in the 12 months prior to enrolling in the study and who had no previous exposure to MS therapy, Tovaxin reduced their ARR by 64% compared to placebo. The overall ARR for Tovaxin-treated patients dropped to 0.18 relapses/patient per year by the end of the 52-week study. Additionally, 76% of Tovaxin-treated patients remained relapse-free at one year compared with 60% of placebo patients.



http://finance.yahoo.com/marketupdate/inplay

good luck if you own! (kei called it...)